[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hormonal-contraception\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hormonal-contraception":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,51,77,105,129],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":25,"briefSummary":27,"conditions":28,"keywords":32,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100551121","phase-4-adaptions-and-resiliency-to-multi-stressor-operations-100551121",false,"NCT06455969","Adaptions and Resiliency to Multi-Stressor OpeRations","Musculoskeletal Resiliency and Adaptation to Sex Steroid Suppression and Replacement During Multi-Stressor Training","ARMOR","Inclusion Criteria:\n\n1. Age 18-40 years\n2. body mass index (BMI) 18-30 kg\u002Fm2\n3. weight stable (±10 lbs) in past 2 months\n4. takes part in moderate physical activity for at least 150 minutes\u002Fweek\n5. currently free of upper or lower body \u002Fextremity injury or impairment\n6. able to commit to study duration\n7. agrees to adhere to study requirements\n8. not taking prescription medications or be willing to refrain from medication prior to and throughout the study period, unless approved by study physician\n9. in women, eumenorrheic (cycles of 26-35 days) OR using monophasic oral contraceptive pills with norethindrone acetate (e.g., first generation progestin) for previous 3 months\n\n1\\) Current smoker 2) current clinical diagnosis of an eating disorder 3) use of medication incompatible with measurement of reproductive and metabolic hormones or which may interfere with any of the study outcomes; with the exception of approved contraceptives for the contraceptive STRESS \\& CONTROL groups 4) current oligo\u002Famenorrhea in women 5) any metabolic or endocrine disease 6) has been diagnosed with a medical condition, physical or psychological, that currently prevents potential subjects from exercising 7) currently pregnant or becomes pregnant during the study 8) history of heart condition OR high blood pressure 9) treating physician requires subject participates in medically supervised physical activity only 10) history of drug addiction, or regular use of recreational drugs 11) currently undergoing treatment for or have a history of mental health conditions 12) Current diagnoses of disorders known to affect bone metabolism including hyperthyroidism, hyperparathyroidism, osteomalacia, Cushing's, diabetes mellitus or renal insufficiency 13) Current use of medications known to affect bone metabolism including estrogens, androgens, anti-estrogens, bisphosphonates (oral bisphosphonates within one year of the baseline visit or IV bisphosphonates within three years of the baseline visit), calcitonin, fluoride, oral or inhaled glucocorticoids, suppressive doses of thyroxine, lithium, pharmacological doses of vitamin D (greater than 2000 IU\u002Fday), anti-convulsants, depot medroxyprogesterone within 6 months; with the exception of approved contraceptives for the contraceptive STRESS \\& CONTROL groups 14) History of deep vein thrombosis, pulmonary embolism, or clotting disorders. 15) History of stroke or myocardial infarction 16) Fracture within the last 6 months. 17) Systolic blood pressure \\> 160 or diastolic blood pressure \\> 95 18) Active substance abuse 19) History of hereditary angioedema 20) History of chest pain at rest, during daily activities of living, or when performing physical activity 21) Musculoskeletal injury removing subject from physical activity for more than a month within the past 2 years 22) Recreational drug use more than 2 times per month in each of the previous 6 months 23) Self-reported vision is worse than 20\u002F20. 24) Personal history or history of a first-degree relative with breast cancer 25) Participated and taken investigational drug in any other clinical trial (including bioequivalence study) within six months prior to study drug administration 26) Diagnosed with eating disorder 27) Have food allergies, intolerance, restriction, or special diet needs 28) History of endometriosis 29) Current diagnosis of reproductive health issues, such as ovarian cysts, PCOS, pelvic lesions, undiagnosed ovarian enlargement 30) Have undiagnosed abnormal vaginal bleeding 31) Currently breastfeeding or within 2 months after stopping breastfeeding 32) Frequent headaches accompanied by vision changes (indicative of possible pituitary pathology)\n\nFor SUPPRESS and REPLACE:\n\n1-32 listed above 33) PSA \\>3 ng\u002FmL) 34) Serum 25-hydroxyvitamin D \\\u003C 20 ng\u002FmL 35) Thyroid dysfunction 36) Serum creatinine \\> 2 mg\u002FdL 37) Personal history or history of a first-degree relative with breast cancer 38) Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \\> 2x the upper limit of normal 39) Serum bilirubin \\> 2 mg\u002FdL 40) Serum alkaline phosphatase \\> 150 U\u002FL 41) Plasma hemoglobin \\\u003C 10 gm\u002FdL 42) Hematocrit \\> 50 43) In men, Serum testosterone level \\\u003C 270 or \\> 1070 ng\u002FdL (\\\u003C 9 or \\> 37 nmol\u002F L) 44) Triglycerides \\> 150 fasting",true,"ALL","18 Years","40 Years",{"count":22,"type":23},120,"ESTIMATED","INTERVENTIONAL",[26],"PHASE4","Non-combat-related muscle, tendon and bone injuries are the most common injuries suffered by military personnel, particularly in new recruits. These injuries impact military readiness and are responsible for roughly 60% of limited duty days, 65% of soldiers who are unable to deploy, and nearly $500 million in medical cost to the government annually in the Army alone. Drug interventions must be studied and developed to prevent these negative outcomes and prepare military personnel for the demands of military service. At the current time, military leadership has identified critical gaps in understanding how to minimize these injuries and train soldiers with drug intervention serving among those gaps.\n\nThe goal of this study is to determine how a hormonal intervention can change muscle, tendon, and bone function as well as physical and psychological performance in response to mental and physical stress. To do so, we will examine sex hormone (testosterone, estrogen) levels, muscle, tendon, and bone images, blood samples, and physical and mental performance. We will look at things like changes in hormone levels, chemicals released from active skeletal muscles, and your body composition. The results from this study will be used to improve physical readiness training in the military with the goal of reducing injuries.",[29,30,31],"Musculoskeletal Injury","Hypogonadism","Hormonal Contraception",[33,34,35,36,37],"Military","Multi-stressor Training","Tendon","Muscle","Bone","RECRUITING","2026-08-14",{"date":41,"type":42},"2026-08-18","ACTUAL",{"date":44,"type":42},"2024-07-15",{"date":46,"type":23},"2027-08",{"name":48,"class":49},"Bradley Nindl","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":56,"acronym":4,"eligibilityCriteria":57,"healthyVolunteers":11,"sex":58,"minAge":19,"maxAge":59,"enrollmentInfo":60,"targetDuration":4,"studyType":24,"phases":62,"briefSummary":64,"conditions":65,"keywords":4,"overallStatus":67,"whyStopped":4,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":71,"completionDateStruct":73,"leadSponsor":75,"locationsCount":50},"100642254","energy-deficiency-on-hormones-in-contraceptive-users-100642254","NCT07651800","Energy Deficiency on Hormones in Contraceptive Users","Effects of a Modest Energy Deficit on Reproductive Hormones Across the Menstrual Cycle in Contraceptive Users","Inclusion Criteria:\n\n* Female, aged 18-35 years\n* Recreationally active (engaging in structured exercise between 8-15 hours per week)\n* BMI of 18.5-29.9 as a BMI below or above these cut points results in highly varied menstrual cycle lengths17\n* Not currently experiencing an eating disorder or disordered eating, or having a diagnosed eating disorder in the last 3 years\n* Non-pregnant or planning to become pregnant\n* Medically free from chronic diseases\n* Currently using one of the following contraceptive methods for ≥3 months:\n\nMonophasic oral contraceptive\n\n* Hormonal intrauterine device (H-IUD)\n* Copper intrauterine device\n* Weight stable (no weight change \\>5% body weight within the past 3 months)\n* Weight greater than or equal to 110 lbs\n* Not suffering from known gynecological disease (i.e., PCOS, endometriosis, etc.) that may influence menstrual cycle regularity\n* Willing and able to maintain current exercise habits throughout the study\n* Willing to follow study dietary guidance to achieve a \\~250 kcal\u002Fday energy deficit during Cycle 2\n\nExclusion Criteria:\n\n* Amenorrhea or oligomenorrhea\n* Perimenopausal or menopausal\n* Currently pregnant, planning pregnancy, or breastfeeding\n* Use of hormonal contraception other than monophasic oral contraceptives or hormonal IUD (implant, nuvaring, etc.)\n* Initiation or change of contraceptive method within the past 3 months\n* Diagnosis of polycystic ovary syndrome (PCOS), endometriosis, hypothalamic amenorrhea, or other known reproductive endocrine disorder\n* Current or history of eating disorder or clinically diagnosed disordered eating\n* Current participation in intentional weight loss or weight gain program\n* Use of medications known to affect metabolism or hormone levels (e.g., systemic corticosteroids, thyroid medications, insulin, GLP-1 agonists)\n* Known metabolic, cardiovascular, renal, hepatic, or endocrine disease\n* Musculoskeletal injury limiting exercise participation within the past 3 months\n* Smoking or nicotine use\n* Contraindications to DXA scanning (e.g., pregnancy, recent high-radiation diagnostic imaging exceeding institutional limits)\n* Inability or unwillingness to comply with study procedures","FEMALE","35 Years",{"count":61,"type":23},30,[63],"NA","The purpose of the present study is to characterize the endocrine and metabolic responses to a modest, short-term energy deficiency (\\~250 kcal\u002Fday) across the menstrual cycle in recreationally active women using different contraceptive methods (oral contraceptive, hormonal IUD, and non-hormonal IUD). This study will leverage daily urinary hormone metabolite tracking and comprehensive metabolic assessments, providing foundational data addressing an important and previously unexamined interaction between energy availability and hormonal regulation in contraceptive users.",[66,31],"Energy Deficiency Due to Short-term Fasting","NOT_YET_RECRUITING","2026-06-10",{"date":70,"type":42},"2026-06-16",{"date":72,"type":23},"2026-09",{"date":74,"type":23},"2027-12",{"name":76,"class":49},"University of Southern California",{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":17,"sex":58,"minAge":19,"maxAge":59,"enrollmentInfo":83,"targetDuration":4,"studyType":24,"phases":85,"briefSummary":86,"conditions":87,"keywords":90,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":50},"100601849","effect-of-different-sex-hormone-profiles-for-the-response-to-physical-training-100601849","NCT07115849","Effect of Different Sex Hormone Profiles for the Response to Physical Training","Inclusion Criteria:\n\n* BMI 19-25\n\nExclusion Criteria:\n\n* Training more than 2 times per week\n* Smoking\n* Pregnancy\n* Taking any medications known to affect the outcome parameters",{"count":84,"type":23},60,[63],"The aim of the project is to elucidate the impact of diverse sex hormone profiles on the adaptability of muscle mass to physical training. Additionally, the project aims to investigate secondary effects on adipose tissue, tendons, and other physiological parameters associated with physical function.",[88,89,31],"Eumenorrhea","Intrauterine Devices, Medicated",[91,92,93,94,95],"IUD","POPs","Progestin","sex hormone profile","physical training","2026-02-27",{"date":98,"type":42},"2026-03-02",{"date":100,"type":42},"2025-08-05",{"date":102,"type":23},"2028-12",{"name":104,"class":49},"University of Aarhus",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":58,"minAge":19,"maxAge":20,"enrollmentInfo":111,"targetDuration":4,"studyType":113,"phases":4,"briefSummary":114,"conditions":115,"keywords":116,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":123,"completionDateStruct":125,"leadSponsor":127,"locationsCount":50},"100586707","quality-of-life-during-different-regimens-of-combined-hormonal-contraceptives-in-women-of-reproductive-age-100586707","NCT06918873","Quality of Life During Different Regimens of Combined Hormonal Contraceptives in Women of Reproductive Age","Inclusion Criteria:\n\n* women of childbearing age (aged 18-40) who seek advice for use of combined hormonal contraception (CHC).\n* stable relationship",{"count":112,"type":23},400,"OBSERVATIONAL","The aim of the present study is to investigate the psychosexual effects of combined hormonal contraception regimens, comparing them in terms of estrogen type and dosage, hormonal combination regimen and different routes of administration, in women seeking a hormonal contraception method to prevent unwanted pregnancies. In particular, the study focuses on the incidence of mood disorders and sexual dysfunctions associated with distress in the entire study population using combined hormonal contraception. It will also examine the incidence of these conditions under the influence of specific combined hormonal contraceptives, as well as whether different types of progestins and the route of administration (oral, vaginal or transdermal) may affect the occurrence of mood disorders and sexual dysfunctions.",[31],[117,118,119],"combined hormonal contraception","female sexual dysfunction","mood disorders","2025-04-02",{"date":122,"type":42},"2025-04-09",{"date":124,"type":42},"2014-05-05",{"date":126,"type":23},"2026-01",{"name":128,"class":49},"Fondazione IRCCS Policlinico San Matteo di Pavia",{"id":130,"slug":131,"hasResults":11,"nctId":132,"briefTitle":133,"officialTitle":134,"acronym":4,"eligibilityCriteria":135,"healthyVolunteers":17,"sex":58,"minAge":19,"maxAge":20,"enrollmentInfo":136,"targetDuration":4,"studyType":24,"phases":138,"briefSummary":139,"conditions":140,"keywords":142,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":157,"lastUpdatePostDateStruct":158,"startDateStruct":160,"completionDateStruct":162,"leadSponsor":164,"locationsCount":50},"100533202","oxytocin-and-reward-processing-in-women-100533202","NCT06222749","Oxytocin and Reward Processing in Women","The Role of Oxytocin in Reward Processing Across the Menstrual Cycle and With Oral Contraceptive Use","Inclusion Criteria:\n\n* Body-mass index (BMI): 18-28 kg\u002Fm2\n* Sex: female (since birth)\n* Normal or corrected vision\n* Natural menstrual cycle (NC) or intake of hormonal oral contraceptives (OC)\n* NC: No hormonal contraception for at least 6 months; regular menstrual cycle (between 25 and 31 days) prior to participation\n* OC: No hormonal contraception for at least 4 months, regular intake of OC pill\n\nExclusion Criteria:\n\n* No German language fluency (due to German language test content)\n* Smoking\n* Medication taken within the last 6 weeks (except for OCs in the respective group)\n* Current neurological or psychiatric disease (anamnestic survey)\n* Current medical problems such as hormonal, metabolic, or chronic diseases (e.g., severe hypertension, diabetes, dysfunctions of the thyroid, or congestive heart failure)\n* Pregnancy, delivery and lactation (current and within the last year; anamnestic survey, current pregnancy test)\n* Premenstrual dysphoric disorder (PMDD), endometriosis or polycystic ovary syndrome (PCOS)\n* Shift work\n* NC: Any kind of hormonal treatment or contraception\n* OC: Any kind of hormonal treatment or contraception (except OCs)\n* Contraindication for MRI:\n* Non-removable metal objects on or in the body\n* Tattoos (if MRI-incompatible according to expert guidelines)\n* Pathological hearing or increased sensitivity to loud noise\n* Claustrophobia\n* Operation less than three months ago\n* Neurological disease or injury\n* Moderate or severe head injury\n* Intake of antidepressants or neuroleptics\n* Restricted vision",{"count":137,"type":23},100,[63],"Oxytocin is a hypothalamic neuropeptide that is best known for its peripheral physiological effects in the female organism i.e., uterine contractions during birth. The neuropeptide furthermore affects reward processing and metabolic functions such as eating behavior and body weight. Oxytocin receptors are present in brain regions associated with the processing of rewards, e.g., ventral tegmental area (VTA), nucleus accumbens (NAcc) and nucleus stria terminalis.\n\nPrevious studies indicate that oxytocin interacts with sex hormones such as estradiol in a sex-specific manner. Despite known sex differences in oxytocin function, most studies i.e., on the metabolic effects of oxytocin in humans have so far focused on young, healthy men.\n\nIntranasal oxytocin administration has emerged as a method to experimentally investigate central nervous effects of oxytocin in the absence of relevant side effects.\n\nIn the proposed study the investigators aim to systematically investigate the acute effect of intranasal oxytocin on reward processing in relation to circulating and synthetic sex hormones in healthy, naturally cycling women and in women taking hormonal oral contraceptive pills. The investigators will administer 24 international units (IU) of intranasal oxytocin vs. placebo and investigate neural correlates in a 3T MRI scanner including functional imaging during a reward processing task, changes in brain anatomy and connectivity. Additionally, metabolic functions, eating behavior and changes in mood and wellbeing will be assessed and blood will be drawn to assess parameters of hormonal and metabolic status.",[141,31],"Menstrual Cycle",[143,144,145,146,147,148,149,150,151,152,153,154,155,156],"Oxytocin","Intranasal oxytocin","magnetic resonance imaging","MRI","fMRI","energy homeostasis","metabolism","reward processing","motivation","menstrual cycle","hormonal contraceptives","sex hormones","eating behavior","women's mental health","2024-02-27",{"date":159,"type":42},"2024-02-28",{"date":161,"type":42},"2024-02-16",{"date":163,"type":23},"2026-12-31",{"name":165,"class":49},"International Research Training Group 2804"]